BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28704126)

  • 1. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
    Tanaka Y; Yamazaki K; Nakajima R; Komatsu S; Igarashi A; Tango T; Takeuchi T
    Mod Rheumatol; 2018 Jan; 28(1):39-47. PubMed ID: 28704126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.
    Takeuchi T; Nakajima R; Komatsu S; Yamazaki K; Nakamura T; Agata N; Igarashi A; Tango T; Tanaka Y
    Adv Ther; 2017 Mar; 34(3):686-702. PubMed ID: 28144917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.
    Emery P; Smolen JS; Ganguli A; Meerwein S; Bao Y; Kupper H; Chen N; Kavanaugh A
    Rheumatology (Oxford); 2016 Aug; 55(8):1458-65. PubMed ID: 27114561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
    Hone D; Cheng A; Watson C; Huang B; Bitman B; Huang XY; Gandra SR
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1564-72. PubMed ID: 23554320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study.
    Anno S; Sugioka Y; Inui K; Tada M; Okano T; Mamoto K; Koike T
    Clin Rheumatol; 2018 Jul; 37(7):1763-1771. PubMed ID: 29525846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A
    Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study.
    van Vollenhoven RF; Cifaldi MA; Ray S; Chen N; Weisman MH
    Arthritis Care Res (Hoboken); 2010 Feb; 62(2):226-34. PubMed ID: 20191522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study.
    Behrens F; Tony HP; Koehm M; Schwaneck EC; Gnann H; Greger G; Burkhardt H; Schmalzing M
    Clin Rheumatol; 2020 Sep; 39(9):2583-2592. PubMed ID: 32206973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Productivity loss of Japanese patients with rheumatoid arthritis - A cross-sectional survey.
    Sruamsiri R; Mahlich J; Tanaka E; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):482-489. PubMed ID: 28849715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.
    Zhang W; Bansback N; Guh D; Li X; Nosyk B; Marra CA; Anis AH
    J Rheumatol; 2008 Sep; 35(9):1729-36. PubMed ID: 18688916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying the economic burden of productivity loss in rheumatoid arthritis.
    Filipovic I; Walker D; Forster F; Curry AS
    Rheumatology (Oxford); 2011 Jun; 50(6):1083-90. PubMed ID: 21245074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.
    Birnbaum H; Pike C; Kaufman R; Cifaldi M
    J Occup Environ Med; 2009 Oct; 51(10):1167-76. PubMed ID: 19786900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Productivity cost model of the treatment of rheumatoid arthritis with abatacept.
    Burton WN; Morrison A; Yuan Y; Li T; Marioni RE; Maclean R
    J Med Econ; 2008; 11(1):3-21. PubMed ID: 19450107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA.
    Bansback N; Zhang W; Walsh D; Kiely P; Williams R; Guh D; Anis A; Young A
    Rheumatology (Oxford); 2012 Feb; 51(2):375-84. PubMed ID: 22179728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of rheumatoid arthritis on the burden of disease in urban China.
    Langley PC; Mu R; Wu M; Dong P; Tang B
    J Med Econ; 2011; 14(6):709-19. PubMed ID: 21899486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
    Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis.
    Zhang W; Bansback N; Boonen A; Young A; Singh A; Anis AH
    Arthritis Res Ther; 2010; 12(5):R177. PubMed ID: 20860837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review.
    Batko B; Rolska-Wójcik P; Władysiuk M
    Int J Environ Res Public Health; 2019 Aug; 16(16):. PubMed ID: 31426543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.